699800 | MPLA (PHAD®)
Monophosphoryl Lipid A (Synthetic) (PHAD®)

MPLA (PHAD®)
Monophosphoryl Lipid A (Synthetic) (PHAD®)

Adjuvant Activity
PHAD®, 3D-PHAD®, and 3D(6A)-PHAD® have been tested extensively in animals using a variety of antigens. In all cases, these adjuvants exhibit a similar activity and safety profile to bacterially-derived MPL. The data above demonstrate the equivalency of the three synthetic adjuvants to the bacterially-derived MPL when presented in a liposomal carrier system (DMPC/DMPG/Cholesterol).
CAS Registry Number is a Registered Trademark of the American Chemical Society
- ChemDraw File
- 3D Structure
- Structure
- Brochure
- 699800 Adjuvant Data
- Certificate of Analysis (Lot No. 699800P-1MG-A-029 and 5086PGA029)
- Certificate of Analysis (Lot No. 699800P-5MG-A-029 and 5086PHA029)
- Certificate of Analysis (Lot No. 699800P-5MG-B-029 and 5086PHB029)
- Certificate of Analysis (Lot No. 699800P-5MG-B-029 and 5086PHB029)
- Certificate of Analysis (Lot No. 699800P-25MG-A-029 and 5086PJA029)
- Safety Data Sheet
Liang T, Leung LM, Opene B, Fondrie WE, Lee YI, Chandler CE, Yoon SH, Doi Y, Ernst RK, Goodlett DR. Rapid microbial identification and antibiotic resistance detection by mass spectrometric analysis of membrane lipids. Anal Chem. 2018 Dec 20. doi: 10.1021/acs.analchem.8b02611. [Epub ahead of print]
PubMed ID: 30571097Lousada-Dietrich, S., Jogdand, P.S., Jepsen, S., Pinto, V.V., Ditlev, S.B., Christiansen, M., Larsen, S.O., Fox, C.B., Raman, V.S., Howard, R.F., Vedvick, T.S., Ireton, G., Carter, D., Reed, S.G., Theisen, M. (2011) A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2 - A GLURP-MSP3 fusion protein malaria vaccine candidate. Vaccine.
PubMed ID: 21349366Coler, R.N., Bertholet, S., Moutaftsi, M., Guderian, J.A., Windish, H.P., Baldwin, S.L., Laughlin, E.M., Duthie, M.S., Fox, C.B., Carter, D., Friede, M., Vedvick, T.S., Reed, S.G. (2011) Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One. 6:e16333.
PubMed ID: 21298114Anderson, R.C., Fox, C.B., Dutill, T.S., Shaverdian, N., Evers, T.L., Poshusta, G.R., Chesko, J., Coler, R.N., Friede, M., Reed, S.G., Vedvick, T.S. (2010) Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf B Biointerfaces. 75:123-32.
PubMed ID: 19748238Coler, R.N., S.L. Baldwin, N. Shaverdian, S. Bertholet, S.J. Reed, V.S. Raman, X. Lu, J. DeVos, K. Hancock, J.M. Katz, T.S. Vedvick, M.S. Duthie, C.H. Clegg, N. Van Hoeven, and S.G. Reed. (2010). A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One 5:e13677.
PubMed ID: 21060869Fox, C.B., Friede, M., Reed, S.G., Ireton, G.C. (2010) Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants. Subcell Biochem. 53:303-21
PubMed ID: 20593273